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Abstract 
An increasing deal of attention is being conveyed on the extra-intestinal manifestations of 
inflammatory bowel diseases (IBD). We compiled the present review in an attempt to upgrade the 
accuracy of the classification of such polymorphic entities. We focused on three patterns. First, the 
conventional extra-intestinal manifestations localized to bone and joints, to the eye, to the biliary tree 
and to the skin. Second, the so-called IBD-like syndromes accompanied by bone marrow-derived 
anomalies of innate or acquired immunity. Third, specific disorders of the skin and of the lungs. The 
extra-intestinal manifestations are thought to derive from an altered gut permeability, the release of 
cross-reacting antigens, and subsequent peripheral inflammation; T helper 17 cells boosted by a 
polymorphic interleukin 23 circuitry would be the main effectors of this chain. Inflammatory bowel 
disease-like pictures would derive from inborn errors of the immune response causing undue 
inflammation home to the gut. Monogenic IBD belong to this subset, and are of specific pediatric 
interest. Psoriasis, chronic obstructive pulmonary disease, and IBD are all inflammatory disorders of 
the barrier organs: skin, lungs, and gut. The demonstration that specific antigen hyper- or 
hyporesponsiveness raised at any of the three districts can modulate the response of the other two 
sites, has led to the innovative concept of a system-wide mucosal immunological organ. An improved 
knowledge of these entities has not only a speculative importance, but can also bear a clinical impact, 
insofar as the extra-intestinal manifestations prove often more disabling than the underlying IBD 
itself.   
 
Key words: Arthritis – Cholangitis – Microbiota - Erythema nodosum - Pyoderma - Uveitis  
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Introduction 
The inflammatory bowel diseases (IBD) (ulcerative colitis and Crohn’s disease) present in Italy and 
in the rest of the Western World with a prevalence reported between 180 and 300 cases/105 and are 
on the rise in emerging countries.1 Pharmacological disease control is still far from perfect,2-5 partly 
reflecting our limited understanding of the pathogenesis of the disease, and its complex phenotypic 
presentation.6 A few years ago, we delineated the concept that, despite an inflammatory core centered 
on the gut, the IBDs include a crucial intertwining of circuits and relevant organ damage that can take 
place beyond the bowel boundaries.7 More recently, we have elaborated on the concept of  IBD-like 
syndrome, and examined the factors, either accompanying or causative, that may play a role.8 
   The envisaging of IBD as a systemic disease has now been fostered by a group examining the extra-
intestinal manifestations (EIM) of IBD.9 We based on the contents of this review, and those of a 
previous one,10 to reappraise such challenging matters.  
 
Materials and Methods 
Data Acquisition 
   To identify all appropriate publications, a PUBMED search of all studies published from 1965 to 
2019 was conducted. The final date was March 16, 2019. The following medical subject headings 
were used and combined: Inflammatory bowel disease, IBD, Crohn’s disease, ulcerative colitis, 
arthritis, cholangitis, microbiota, psoriasis, erythema nodosum, pyoderma, uveitis, chronic 
obstructive pulmonary disease (COPD), amyotropic neuralgia, hidradenitis suppurativa, innate 
immunity, adaptive immunity, Signal Transduction and Activation of Transcription (STATs), X-
linked apoptosis inhibitor (XIAP), Protease a disintegrin and metalloproteinase (ADAM) 17. 
 The search was also performed using reference lists from published articles. The titles of these 
publications and their abstracts were scanned in order to eliminate duplicates and irrelevant articles.  
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   We evaluated literature data on the basis of the classification of the IBD-associated EIM, as 
exemplified below. 
1) Classically named EIM 
a) Rheumatologic phenomena (grossly divided in axial versus peripheral); 
b) eye phenomena (e.g., uveitis); 
c) liver/biliary tree pathology (e.g., cholangitis); 
d) skin manifestation: erythema nodosum, pyoderma; 
e) rare phenomena: e.g., hidradenitis suppurativa, amyotrophic neuralgia and others. 
 
2) Major accompanying pathologies 
      a) Pathology inscribing an IBD-like phenomenon:  
       - innate immunity; 
       - adaptive immunity; 
       - key molecule clusters: STATs, XIAP, ADAM 17. 
     b) Contiguous pathology (affecting functionally related systems): 
- psoriasis (skin dysfunction); 
- COPD. 
 
Results 
   The classically defined phenomena enumerated in (1) (conventional EIM) are often tentatively 
understood under a common comprehensive hypothesis. It is envisaged that the gastrointestinal 
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mucosa can initiate immune responses at extra-intestinal sites because of the existence of shared 
epitopes between luminal and extra-luminal antigens in the presence of a favoring genetic tendency. 
11-13 The emphasis recently placed on gut microbiota and their role in homeostasis has further enriched 
this mind frame: indeed, Toll-like receptors (TLR) are known to correctly effect innate immune 
responses in the presence of correctly working microbiota; disturbing microbiota composition or 
function can lead to wrong TLR signaling, undue inflammation, and, among others, arising of any 
EIM.14 We now proceed by examining the updated theories on the pathogenesis of the conventional 
EIM as listed in 1). 
1) Classically named EIM 
The rheumatologic phenomena        
   Occurring in approximately 20 to 30% of patients with no gender differences,15 joint manifestations 
are the most common EIMs in IBD patients. Peripheral arthropathy and axial arthropathy are included 
in this category. The former is further divided in type 1 or type 2 according as to whether less or more 
than 5 joints are respectively involved.10 Recent attempts to clarify the pathogenesis of these entities 
have led to the conceptualization of a “gut-synovium axis”16 for which some notions on the 
physiologic and pathophysiologic working of T helper (Th)17 cells is essential.  
   Similarly to Th1, Th2, and FoxP3+, also Th17 cells17 derive from naïve T-cells in secondary 
lymphoid tissues in response to antigen presentation. Characteristically expressing interleukin (IL)-
17A, IL-17F, IL-21, and IL-22, Th17 lymphocytes have long been thought to exert a primary line of 
defense against various invaders, including viruses and fungi; in the absence of any infection, their 
primary migration site is the intestine.18 However, it has become evident that Th17 cells do express 
certain trafficking receptors to migrate specifically to target tissue sites, including the synovial 
structures that are our topic at this point. The story began with the observation that Th17 cells can 
induce bone destruction in autoimmune arthritis by acting as an osteoclastogenic helper T-cell subset. 
19 The presence of the chemokine receptor 6 (CCR6) receptor has proven central to this Th17 cell 
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function. Indeed, CCR6 has shown preponderant affinity for the chemokine (C-C motif) ligand 
20 (CCL20).20 Highly expressed on the synovial cells of arthritic joints, CCL20 can thus be 
interpreted as the receptor substrate underlying the osteoclastogenic potential of Th17 cells: injection 
of anti-CCR6 abolished experimental autoimmune arthritis in animal models.20 The Th17 loops are 
under the strong influence of IL-23 and its polymorphism.21 
Besides this general template, several working hypotheses have been proposed. 
a) A leaky intestinal barrier may initiate a response against luminal bacteria with release of 
inflammatory mediators.22 
b) Pathology is triggered by adhesion of intestinal lymphocytes to synovial blood vessels, 
mediated by the action of vascular adhesion protein (VAP)-1, a cell-surface expressed 
oxidase.23,24 This hypothesis centers on the facilitating roles of abnormal human leukocyte 
antigen (HLA) loci (B35 and/or B44).25 
c) Role of polymorphisms. Polymorphic caspase activation and recruitment domains (CARD) 
and nucleotide-binding oligomerization domain (NOD) could affect wrong responses to 
bacterial agents and systemic repercussion;26 a Th17 mediated inflammation fueled by 
polymorphism of IL-23 has been indicated as relevant in the genesis of ankylosing spondylitis. 
27,28 These data are supported by the efficacy of an anti-IL23 drug (ustekinumab) both in IBD 
and in psoriatic arthritis.29 
 
Eye phenomena 
Their reported prevalence has varied between 1.1 and 10%.30 It is thought that HLA specifity variants 
may play a major role in the pathogenesis: the genetic propensity could then overlap with a diminished 
intestinal barrier for an environmental trigger to induce T-cell activation and clinical disease. Most 
investigators’ attention has focused on the role of HLA B27. 31 Its association with uveitis and entero-
hepatic arthropathy could interestingly justify the frequent finding of associated ocular manifestations 
and joint involvement in many IBD cases.32 
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Liver/biliary tree 
   The epidemiological importance of this association is underscored by the finding of abnormal liver 
function tests in up to 1/3 of IBD patients.10 Primary sclerosing cholangitis (PSC) is the most feared 
manifestation of this dangerous gut/liver axis.33 It is characterized by chronic inflammation, strictures 
in intra- and more often extra-hepatic ducts; unfortunately, there is not yet a medical treatment able 
to prevent or modify the natural history towards liver cirrhosis and failure, so orthotopic liver 
transplantation is the only viable solution for patients presenting with advanced disease.34  
Autoimmune factors are commonly invoked, including the well-known serologic markers p-
antineutrophil cytoplasmic antibodies (ANCA), antinuclear antibodies (ANA), anti-smooth muscle 
antibody (ASMA).35 A genetic predisposition to PSC is highlighted by the frequent detection of HLA-
B8 and HLA-DRB1 specificities.36 Pathogenetic theories do not fail to emphasize the hypothetic role 
of a response to a bacterial contamination of biliary tree.37 Patients with Crohn’s disease and abnormal 
liver function tests but without PSC or autoimmune hepatitis do not have higher risks of liver disease 
progression (hence, significant fibrosis38) than the general population.39,40  
 
Skin manifestations 
   This category traditionally includes erythema nodosum and pyoderma (Figure 1), and may affect 
1-15% of all IBD patients.41 A very popular hypothesis holds that a cross response may take place to 
antigens that are shared between the gut flora and the skin. This would evolve into a hypersensitivity 
reaction with immune complexes forming in blood vessels adjacent to subcutaneous fat.42 In the case 
of pyoderma investigators stress a heightened expression of pro-inflammatory cytokines: IL8, IL16, 
IL17, tumor necrosis factor (TNF)-alpha.43 As usual, the influence of a permissive HLA expression 
is invoked: B15 has been associated to development of erythema nodosum;44 TRAF3IP2 an 
intermediate of the inflammatory response and possibly a driver of IL17, has been summoned for 
both erythema and pyoderma.45 Unfortunately, a drug acting specifically against IL17 resulted 
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efficacious against rheumatic and cutaneous inflammatory disorders, but a trigger for IBD reaction 
and new-onset.46  
Rare phenomena 
   Rarely, IBD may be accompanied by unusual manifestations involving various organs. We hereby 
include an arbitrary selection of these events. 
a) Hidradenitis suppurativa  
This co-morbidity has recently been exhaustively reviewed. Publication of the first case series 
dates back to 1993. Pooled analysis of four studies indicates a prevalence of 12.8%; Crohn’s 
diseases, female gender, and tobacco addiction seem to be risk factors. Anomalies of the TLR 
and NOD innate immune responses are suspected to play a favoring role. The frequent finding 
of Staphylococcus aureus in the lesions may be a witness of these hints. Hidradenitis 
suppurativa seems to respond to the same immune modulatory drugs (including anti-TNF 
molecules) as the underlying IBD.47 
b) Parsonage-Turner (PT) syndrome (amyotrophic neuralgia)  
PT patients experience sudden violent pain of girdle muscles, followed by profound motor 
weakness, and muscle atrophy.48 A hereditary (often bilateral) form and an idiopathic 
presentation have both been described.49 Interestingly, the literature lists only two cases of PT 
as a comorbidity of IBD. The first one dates back to 2014.50 The second one, included in our 
out-patient series,30 reports a middle-aged woman presenting with bilateral PT that flared 
synchronously with a pancolitis. Again, simple coincidence must be excluded; however, this 
disabling disorder calls for neurologists to be included in the list of IBD caretakers. 
c) Posterior segment ophthalmic manifestations  
Posterior segment manifestations are not usually described. The recent literature describes a 
28-yr old female patient who underwent resection for Crohn-induced bowel stenosis.51 Owing 
to significant loss of visual acuity, she underwent complete diagnostic work-up. The results 
led to diagnose severe ischemic retinopathy secondary to Crohn’s disease. In the discussion 
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the authors emphasized that an ileal or ileo-colonic localization, and presence of another co-
morbidity (e.g., arthralgia) may effect a 33% increment of the risk of ocular involvement.   
d) Bilateral Achilles tendinitis 
The recent literature reports on a single case of bilateral Achilles tendinitis coincidental with 
active ulcerative colitis. This 26 yr old female, presenting with active disease deserving 9 
marks of the Lichtiger score, responded to mesalamine; the bilateral tendinitis followed 
clinical remission from her IBD. Though simple coincidence could not be excluded, the 
authors purport that this instance can correctly be added to the list of the IBD dependent 
EIM.52 
e) Pancreatitis  
Patients with Crohn’s disease, specifically if females, are reportedly at a four-fold risk of 
experiencing acute pancreatitis.53 Reasonable causative factors include gallstones and drugs. 
The latter may most often include mesalamines and thiopurines.54,55 Whether acute 
pancreatitis has to be classified as a true EIM is a matter for debate. Type 2 autoimmune 
pancreatitis may be co-morbid of UC; yet the type 1 variant, with its IgG4 excess seems not 
to associate preferentially with either IBD. Recent evidence from cellular studies would favor 
the EIM bias: T-cells bearing receptors for mucin-1 (the composition of which is abnormal in 
IBD) have been documented to migrate to both gut and pancreas.56  
f) Cogan’s syndrome 
This syndrome, first described in 4 cases by D. Cogan,57 is nowadays understood as a 
vasculitis. In its typical presentation, the patient experiences the abrupt onset of audio-
vestibular symptoms including vertigo and tinnitus. Deafness may ensue with any delay. 
Within any interval, even of years, ocular symptoms may then develop with interstitial 
keratitis. Lack of the latter justifies identification of a so-called atypical Cogan. Prompt 
diagnosis of Cogan’s syndrome may not be within the reach of any physician; irrespective of 
the time lag with which the correct diagnosis is made, Cogan’s syndrome often takes to 
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deafness. Most cases are bilateral, though cases of monolateral Cogan’s syndrome have been 
claimed. The literature reports some 200 cases, with less than 20 being associated to an IBD.58 
We have recently followed a young male patient, with a Crohn’s history in siblings, who 
presented with acute vestibular syndrome in 1999 on top of aggressive Crohn’s invading 
esophagus and stomach. He responded to high-dose steroids and then received maintenance 
with thiopurines. In these days, the patient’s Crohn’s disease is in remission on thiopurines; 
monolateral deafness and tinnitus have required an audio-therapeutic device; no keratitis has 
appeared yet.  
2)Major accompanying pathologies 
   Regarding major accompanying pathologies, in the last decade, we have begun to appreciate that a 
deal of effector immunologic circuitry is taking place beyond the bowel borders; while gut-generated 
events may hit locations afar (the EIM above are an example), systems afar, often entailing innate 
and acquired immunity, may generate inner gut pathology, allowing a sort of bi-directional traffic. 
The result of the latter events is often an IBD-like pathology that is indistinguishable from genuine 
IBD,59 but, specifically if aroused by anomaly of a non-redundant yet vital cell function, may prove 
life threatening in the pediatric life phase (monogenic IBD).60,61 We have recently compiled a review 
of these conditions,8 here we limit ourselves to an arbitrarily selected presentation. 
 
Pathology inscribing an IBD-like phenomenon 
a) X-linked apoptosis inhibitor  
Apoptosis is a crucial cell homeostasis regulator, under the opposing influences of pro- and 
anti-apoptotic signaling molecules.62 Overexpression of anti-apoptotic signaling may be at the 
basis of both some cancers and severe inflammatory disorders. All anti-apoptotic molecules 
share the ability to bind caspases through baculovirus IAP repeat domains (BIR).63 The family 
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of the XIAP is the most potent and best studied: it effectively neutralizes caspases 3, 7, and 9. 
XIAP invariably leads to a key triad of clinically severe manifestations: sensitivity to Epstein-
Barr virus induced histiocytosis, recurrent splenomegaly, and IBD.64 Few pediatric cases of 
XIAP malfunction have recently been published. Genetic analysis of the first one revealed a 
G to A substitution at a highly conserved position causing a cysteine to tyrosine switch on the 
XIAP molecule; this child underwent eventual progenitor cell transplant with immediate 
response,65 like another similar case.66 Differently, another cases67,68 did not undergo bone 
marrow cell replacement, ran a rocky course, and at least one is now dealing with unchecked 
fistulizing Crohn’s disease. 
b) The signal transduction and activation of transcription  
They are a family of mediators of cell signaling during immune responses, with their intact 
action depending on the protein family Janus kinase (JAK), which can activate specific 
STATs to downstream signaling.69 Studies in animal models70 have shown that loss of STAT 
function: (a) favors chronic enterocolitis; (b) increases sensitivity to apoptosis, impairs wound 
healing, increases sensitivity to endotoxin. An intact STAT signaling through the IL10R is 
necessary to prevent such changes. The consanguineous members of two unrelated families 
have recently been diagnosed with incurable skin and respiratory infections: documentation 
of loss-of-function mutation of IL10R disclosed the cause of the life-threatening disorder and 
indicated successful bone marrow replacement.71 JAK inhibitors, in the form of oral small 
molecules, are new drugs recently revenue available in the therapeutic armamentarium for 
ulcerative colitis.72 
c) Protease a disintegrin and metalloproteinase-17 
It is a disintegrin metalloprotease capable to cleave TNF, L-selectin, and epidermal growth 
factor receptor (EGFR) ligands from plasma membranes: when up-regulated, ADAM-17 can 
control cancer and inflammation.73 The multiplex dysfunctions of three children born to 
consanguineous parents have recently been described and attributed to failure to activate 
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STAT3 via a normally shed EGFR (consequence of lacking ADAM-17). The multiple skin, 
hair, and gut lesions of these subjects responded to treatment and were compatible with a 
nearly normal life.74 Incidentally, these findings discourage a strategy of abolishing ADAM-
17 to treat inflammatory disease suspected to be due to excess TNF release.  
The reader is referred to our review for an exhaustive coverage of this topic.75 
 
Contiguous pathology (affecting functionally related systems) 
Psoriasis 
If psoriasis is a peculiar inflammatory dysfunction of the skin as a barrier organ, it cannot be described 
without IBD in mind. Clinical, pathogenetic, and genetic observations contribute to pose the two 
affections in contiguity: 1) Psoriasis is seven times more common in Crohn’s disease patients than 
controls; 2) ten percent of Crohn’s disease patients have first-degree relatives with psoriasis; 3) both 
disorders do respond to the T-lymphocyte modulator drug cyclosporine,76 to methotrexate,77 anti-
TNF inhibitors,77 anti-IL-12/23 ustekinumab.29 Modern theories on the pathogenesis of psoriasis do 
no longer speculate on autoimmunity, but emphasize the role of a malfunctioning innate immunity 
combined with variations of skin microbiota. Of the four most studied peptidoglycan recognition 
proteins, the genes of two of them (peptidoglycan recognition proteins [PGRP]-3 and PGRP-4) on 
chromosome 1q show polymorphism in psoriasis.78,79 Such theory could not be viable without 
stressing the role of skin microbiota.80 Indeed, it is now appreciated that microbiota species variation 
can modify the psoriatic phenotype (e.g. guttate psoriasis seems to be connected with presence of 
Streptococci in the throat) and the localization of the plaques.81 Not only can the microbiota phylum 
with its specific immune reaction modify local skin conditions, but also remote immunity, e.g. lung 
immunity can be influenced by skin inflammatory events as driven by resident microbiota.82 This may 
serve as an introduction to the next paragraph on gut-lung dialogue.  
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The dialogue between gut and lung (COPD) 
   Gut and lung share anatomic and embryonic commonalities. These materialize at various levels, as 
detailed below. 
a) Clinics 
The IBDs may exhibit subclinical lung involvement detectable as bronchial hyper-reactivity 
in 48% and 71% respectively of adult and pediatric patients.83 IBD patients are at an increased 
risk for COPD,84 COPD develops independently from smoking habits;85 COPD patients have 
recently been shown to carry a mutated NOD gene, in analogy with the IBDs.86 
Furthermore, granulomatous and interstitial lung disease are rare respiratory disorders that 
have been associated with IBD, that require hospitalisation and systemic steroids. In a recent 
case series half of cases were drug-related but there was no signal of relationship between 
IBD therapy and the onset of interstitial lung disease.87 More studies are needed to investigate 
the pathogenesis and causative association. 
b) Immunology (vaccination studies) 
Diet fibers in the gut can regulate lung immune responses.88 Asthmatics may have allergic 
lung disease with high eosinophil numbers, these cells utilizing the same syalomucin CD34 
to enter gut and lung.89 Gut challenge with a given antigen may protect from future airway 
disease.90 Maneuvers of mouth–driven desensitization can downregulate Th2 responses at 
lung level.91 
c) Microbiota 
A diminished microbiota diversity (such as in inflammatory gut disorder) reduces availability 
of short chain fatty acids, hence produces poor shaping of lung immune environment.92 TLR-
like responses need normal gut microbiota to respond to ligands.93 Wrongly gut-initiated TLR 
signaling induces abnormal inflammatory lung responses.  
d) Candidate mediator molecules 
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The thymic stromal lymphopoietin protein (TSLP)94 (constitutively expressed by intestinal 
epithelial cells) can regulate responses at body interface (mucosae-skin-ocular tissues) to 
Th2-driven allergic responses.95  
The bulk of this evidence speaks in favor of a system-wide mucosal immunological organ. 
 
Discussion 
   Current knowledge and understanding holds the gut as the prototype barrier organ wherein the 
dialogue with the “outside” is finely handled in a swing between inflammation (active defense) and 
tolerance (preservation of integrity).96 The data compiled above, though arbitrarily selected and 
partial, indicate that the gut, and particularly the colon, are constitutively the objects and the drivers 
of bidirectional dynamics whereby inner phenomena may materialize at the periphery (the EIM are 
an example), and conditions afar may perturb the inner events and create disease (e.g., genetic 
variants).  
Specifically, the IBD-associated EIM mainly recognize the following mechanisms: 
1) an increased colon permeability with massive antigen release to the periphery; 
2) maturation of bone-destructive Th17 cells; 
3) systemic effects of microbiome; 
4) generalized modulation of mucosal response (gut-lung axis). 
   Correct recognition of these complications may help the internist to suspect IBD disguising under 
an unusual EIM, and the IBD caretaker to decide to call on a second line other specialists to best help 
the patient. This is so important, inasmuch as often the EIMs are more threatening or disabling than 
the underlying IBD itself.   
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